We next asked whether IHC would be associated with NF1 genomic status and found positive phospho-ERK immunostaining to be associated with NF1 genomic loss (p = 0.045, Supplementary Table 5), supporting prior observations of a similar correlation in mesenchymal GBM [21]. This evidence concerns the gene NF1 and glioblastoma.